Medical Laboratory Center, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China; School of Public Health, Nantong University, Nantong, Jiangsu Province, China.
Clin Biochem. 2013 Oct;46(15):1590-4. doi: 10.1016/j.clinbiochem.2013.06.008. Epub 2013 Jun 18.
The purpose of our study was to investigate the serum levels of soluble a-proliferation-inducing ligand (sAPRIL) in patients with colorectal cancer (CRC), benign intestinal disease and healthy volunteers and explore the potential possibility of sAPRIL severing as a CRC biomarker.
Our investigation was conducted on 35 blood samples obtained from CRC patients, 32 blood samples from patients with benign intestinal diseases and 31 blood samples from healthy volunteers. The sAPRIL concentrations were examined by an enzyme-linked immunosorbent assay (ELISA) and data were analyzed with non-parametric Mann-Whitney U-test and X²-test. The correlation relationship between sAPRIL and CEA, as well as sAPRIL and CA19-9 was assessed by non-parametric Spearmen's correlation test, respectively.
The median value of sAPRIL in the malignant group was 10.43 ng/mL, compared with those of the benign group (4.89 ng/mL) and control group (3.30 ng/mL), respectively, which had an obvious significance (P<0.0003). Area under the receiver-operating characteristic (ROC) curve for sAPRIL was 0.854 (95% CI, 0.776-0.933). The optimal cut-off level of sAPRIL was 5.49 ng/mL. Serum sAPRIL had a positive correlation with CEA (r=0.637, P=0.000) and CA19-9 (r=0.357, P=0.008) in 35 patients with colorectal cancer. sAPRIL showed higher sensitivity (82.9%) than those of CEA (74.3%) and CA19-9 (65.7%) in CRC, respectively.
The results indicated that serum sAPRIL, as a potential biomarker, had a positive diagnostic value for colorectal cancer.
本研究旨在探讨结直肠癌（CRC）患者、良性肠病患者和健康志愿者血清中可溶性增殖诱导配体（sAPRIL）的水平，并探讨其作为 CRC 生物标志物的潜在可能性。
本研究纳入了 35 例 CRC 患者、32 例良性肠病患者和 31 例健康志愿者的 35 份血样。采用酶联免疫吸附试验（ELISA）检测 sAPRIL 浓度，并采用非参数 Mann-Whitney U 检验和 X²检验分析数据。采用非参数 Spearman 相关检验分别评估 sAPRIL 与 CEA 以及 sAPRIL 与 CA19-9 的相关性。
恶性组 sAPRIL 的中位数为 10.43ng/ml，明显高于良性组（4.89ng/ml）和对照组（3.30ng/ml）（P<0.0003）。sAPRIL 的受试者工作特征曲线（ROC）下面积为 0.854（95%可信区间，0.776-0.933）。sAPRIL 的最佳截断值为 5.49ng/ml。35 例 CRC 患者血清 sAPRIL 与 CEA（r=0.637，P=0.000）和 CA19-9（r=0.357，P=0.008）呈正相关。sAPRIL 的敏感性（82.9%）明显高于 CEA（74.3%）和 CA19-9（65.7%）。
血清 sAPRIL 作为一种潜在的生物标志物，对结直肠癌具有阳性诊断价值。
